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Abstract
The objective of the present study was to analyze the pattern of oral contraceptive (OC) use in teenagers and to examine the relationship
between OC use and other cardiovascular risk factors. The study was conducted in 24 Belgian secondary schools. Most students (1526
adolescents aged 12–17 years) agreed to participate (participation rate: 83.6%). Smoking, physical activity habits, menarche, and OC use
were assessed by a self-administered questionnaire. Total cholesterol level, blood pressure and anthropometric measurements were also
measured. Fourteen per cent of mature girls (14%, n 5 92) were OC users. Two-thirds of them (66.3%, n 5 61) were taking OC which
contained either gestodene or desogestrel. Blood pressure and BMI were similar for OC users and non-users. Total cholesterol level was
significantly higher in OC users than in non-users (191 mg/dL versus 172 mg/dL). Logistic regression model confirmed the significant
influence of OC use on total cholesterol level (OR 5 3.08). OC users were also often smokers (39% versus 20% for non-users). In
conclusion, the present study has found significant relationships between OC use and cardiovascular risk factors i.e., high total cholesterol
and smoking. The first implication is a need for further research on lipoprotein profile in young OC users. Secondly, the combined use of
OC and smoking in teenagers calls for preventive actions. © 2000 Elsevier Science Inc. All rights reserved.
Keywords: Oral contraceptives; Cardiovascular risk factors; Adolescence
1. Introduction
Epidemiological data on oral contraceptive (OC) use
during adolescence are scarce, although respectively, two
studies have estimated a prevalence equal to 17 and 28% in
16-year-olds [1,2]. However, this medication might have
effects on the users’ cardiovascular risk factors. Many stud-
ies have analyzed and reviewed them in adult women [3–7].
In particular, the effects of third-generation pills on the risk
of thromboembolism or myocardial infarction have been
carefully studied [8–12]. Little is known on the health
effects of OC use during adolescence. In particular, OC
users from this age group have often a different lifestyle
from the other girls. The combination between these factors
and OC use might have an influence on their health. The
objective of the current study was therefore to analyze the
association between OC use and other cardiovascular risk
factors in a population of Belgian adolescents.
2. Materials and methods
2.1. Survey population
The present survey was carried out in the southern part of
Belgium i.e., the province of Luxembourg. Eligibility cri-
teria were age (12–17 years), Belgian nationality, and res-
idence in the province. The participants were recruited by a
multiclustered sampling technique. First, twenty-four sec-
ondary schools were randomly selected out of the 48
schools in the province. Secondly, a type of education was
selected in each school. Belgian adolescents have the choice
between higher learning education (i.e., theoretical courses)
and technical education (including practical courses). Either
the higher learning education or the technical learning ed-
ucation was randomly chosen in each school, with proba-
bility proportional to the students’ distribution in the prov-
ince. Finally, classes were taken at random as cluster units
within the education type selected for the school. The eli-
gible population in the selected classes had 1,826 subjects.
Most of them (83.6%, n 5 1,526) participated in the study
i.e., 742 boys and 784 girls. The characteristics of the
participants are displayed in Table 1. Of the 300 non-
respondents, 108 were not at school during the survey and
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192 subjects refused to participate. The first reasons put
forward were recent medical examination (n 5 31), omis-
sion of the appointment (n 5 24) and parental refusal (n 5
19). Ethical approval was secured beforehand and written
consents were obtained from all participants.
2.2. Data collection
Information on pubertal status and OC use was collected
through a confidential self-administered questionnaire (i.e.,
formula and duration of use). Other questions on lifestyle
included smoking and physical activity habits. Blood pres-
sure, anthropometric indices measurement, and total cho-
lesterol level were also measured. Blood pressure measure-
ment was carried out according to the Task Force on Blood
pressure in children [13]. The anthropometric measure-
ments (i.e., height, weight, triceps, and subscapular skin-
folds) followed the guidelines of the World Health Organi-
zation [14]. Total cholesterol levels were analyzed
according to the recommendations of the expert panel on
high blood cholesterol in children [15]. The measurement
was performed using the Reflotron® method [16]. Quality
control procedures included double measurements by exter-
nal observers, checks at data entry and during data process-
ing.
2.3. Statistical analyses
Statistical analyses were performed using a SAS® statis-
tical package [17]. Statistical t-tests were used for compar-
ing 2 means and analysis of variance was applied for more
than two subgroups. x2 tests were used for categorical
variables and logistic regression analysis for the relation
between OC use and other cardiovascular risk factors.
3. Results
Six-hundred-fifty-two girls (83.7%, n 5 652) had had
their menarche. The median age of menarche was 12.7
years. Fourteen per cent of mature girls (14%, n 5 92) were
OC users and the mean duration of use was 11 months (95%
CI: 1–36 months). The prevalence of OC use increased from
2 to 34% between 14 and 17 years of age (respectively, 2%,
11%, 18%, and 34% in 14, 15, 16, and 17 year olds) (Table
2). Table 3 summarizes the formulas of the OC used by the
participants. Most of them used low-dose pills with gesto-
dene or desogestrel (mono- or triphasic formulas).
Monophasic formulas containing either cyproterone or
norgestimate were also reported. Levonorgestrel was less
frequently used.
Table 4 compares the risk factors between OC users and
non-users from the same age group (i.e., the 15–17 year
olds). Systolic blood pressure level was similar in both
groups (i.e., 122 mmHg) and diastolic blood pressure did
not differ significantly between OC users and non-users
(i.e., 72 and 74 mmHg, respectively, p for the difference .
0.10). Body mass index was also similar in OC users and
non-users (21.6 and 21.5, respectively). The major finding
was the significant difference in total cholesterol level be-
tween users and non-users. OC users had a mean total
cholesterol equal to 191 mg/dL (SD 5 34 mg/dL) whereas
the non-users exhibited a mean equal to 172 mg/dL only
(SD 5 30 mg/dL). The influence of OC use on total cho-
lesterol was further analyzed by a weighted logistic regres-
sion model with total cholesterol as dependent variable. The
results confirmed that OC use was significantly (OR 5 3.08,
p ,0.01) associated with high cholesterol level whereas the
other factors (e.g., age, BMI, physical activity) were non-
significant.
Sixty-one OC users (n 5 61) were taking formulas con-
taining either desogestrel or gestoden. Their total choles-
Table 1
Characteristics of the participants
Boys Girls
Age N % N %
12 years 86 12 96 13
13 years 155 21 145 18.5
14 years 138 18.5 119 15
15 years 130 17 147 18.5
16 years 139 18.5 139 17.5
17 years 94 13 138 17.5
All 742 100 784 100
Table 2
OC use by age group
Age No. OC users % OC users in
the age group
12 years (n 5 96) 0 —
13 years (n 5 145) 0 —
14 years (n 5 119) 3 2%
15 years (n 5 147) 17 11%
16 years (n 5 139) 25 18%
17 years (n 5 138) 47 34%
All girls (n 5 784) 92
Table 3
OC users: detailed formulas (unknown: n 5 4)
No. Type EE Progestin (mg)
26 Monophasic 0.030 mg Gestodene (0.075)
19 Triphasic 0.03/0.04/0.03 Gestodene (0.05/0.07/0.1)
14 Monophasic 0.020 mg Desogestrel (0.15)
12 Monophasic 0.035 mg Cyproterone (2)
8 Monophasic 0.035 mg Norgestimate (0.025)
3 Triphasic 0.03/0.04/0.03 Levonorgestrel (0.05/0.075/0.125
2 Monophasic 0.030 mg Desogestrel (0.15)
2 Monophasic 0.030 mg Levonorgestrel (0.15)
1 Monophasic 0.035 mg Norethisterone (1.0)
1 Biphasic 0.05 mg Levonorgestrel (0.05–0.125)
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terol and blood pressure levels were compared to the values
of the other OC users. Total cholesterol levels were similar
in both groups (191 mg/dL ) and blood pressure levels were
slightly lower in third generation OC users (i.e., 122 mm Hg
versus 125 mm Hg for SBP and 73 mm Hg versus 76 mm
Hg for DBP). These differences did not reach the level of
statistical significance but the small group sizes did not
allow for drawing definitive conclusions.
Finally, smoking and physical activity habits were com-
pared between OC users and non-users. Both groups re-
ported similar leisure-time physical activity i.e., a mean of
5.5 hours per week. Forty percent (40%, n 5 35) of OC
users were smokers versus 25% (n 5 82) of non-users (p for
the difference ,0.01). The combined use of OC and smok-
ing was associated with the education of the participants.
Thirty percent (30%, n 5 52) of the girls in the technical
option were OC users and nearly half of them were also
smokers (46%, n 5 23). On the opposite, 16% (n 5 40) of
the adolescent girls in the higher learning option were OC
users and 30% of them were also smokers.
4. Discussion
The first objective of the present study was to analyze the
prevalence of OC use in this adolescent population. The
participants represented 8% of the adolescents of the prov-
ince and the participation rate was high (83.6%). A quarter
(26%) of the teenagers aged 16–17 years was OC user. This
proportion is similar to the proportion obtained in a sample
of 16-year-old Finnish girls but lower than the prevalence
recorded in a study from The Netherlands [1,2]. The last
Belgian Health Interview survey has found that OC was the
first contraceptive method used in 15–17 year olds i.e., 85%
of the interviewees using a contraceptive method were tak-
ing OC [18]. The prevalence of OC use in 15–17 year olds
was equal to 28.1% in this national survey. The present
study had a prevalence equal to 21% in the same age group,
which might be explained by the setting of the study i.e.,
secondary schools in a rural area. By comparison, 69% of
the women from the same province use a family planning
method and in particular, 42% are OC users [18].
The second objective of the study was to analyze the
relation between OC use and cardiovascular risk factors in
teenagers. Consequences of OC use have been widely in-
vestigated in adult women but less studied in adolescents.
Recommendations for the prescription of OC to adolescents
are, therefore, derived from the recommendations written
for adult women [19–21]. The common effects of OC use
include hypercoagulation, increase in blood pressure, li-
poprotein and carbohydrates changes, weight gain, and
headaches. These side effects have decreased with new
formulas, containing less estrogen and new progestin com-
ponents. However, in the current study, OC use influenced
substantially the adolescents’ total cholesterol level. The
difference between users and non-users was large (19 mg/
dL), even after a short duration of use (90% of the users had
been taking their OC for less than 2 years). The influence of
OC use on total cholesterol level has been demonstrated in
other studies conducted among adolescents [22,23]. How-
ever, caution is needed in the interpretation of this high total
cholesterol level as the lipoprotein profile change depends
on the OC formula. Third-generation formulas containing
either gestodene or desogestrel have been found to induce
beneficial effects on lipoprotein profile e.g., a slight rise in
HDL-cholesterol [24–27]. Research in young populations
is, therefore, needed to confirm these positive effects in
adolescents. The new OC formulas are also supposed to
have little influence on blood pressure level [3,26,28]. The
present study supports this hypothesis as no significant
difference in blood pressure was found between OC users
and non-users. Finally, the absence of effect on weight
confirms the results of another study conducted in adoles-
cents [29].
As a final point, an important finding was the high
smoking prevalence in young OC users. Forty percent of
them were smokers in comparison with a quarter of the
non-users group. This association was also reported in other
adolescent and adult populations [22,30–32]. The present
study showed that the combined use of OC and cigarettes
existed in one out of 10 girls aged 15 to 17. This association
was more frequent in adolescents with a technical educa-
tion. This finding has important consequences for planning
preventive actions.
5. Conclusion
OC use in teenagers deserves special attention given its
high prevalence coupled with potential health consequences
Table 4
Comparison of risk factors between OC users and non-users aged 15–17 years
OC user (n 5 89) Non-users (n 5 329) p-value for the
difference
BMI (S.D.) 21.6 21.5 .0.10
Systolic BP (S.D.) 122 mmHg (10.5) 122 mmHG .0.10
Diastolic BP (S.D.) 72 mmHg (9.8) 74 mmHg (9.8) .0.10
Total cholesterol (S.D.) 191 mg dL21 (34) 172 mg dL21 (30) , 0.001
Smoking prevalence 40% (n 5 35) 25% (n 5 82) ,0.001
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(including the associated lifestyle habits). In particular, this
study has shown that the level of total cholesterol was
significantly higher in OC users than in non-users. Further
studies should analyze the impact on the lipoprotein profile.
Moreover, OC users are frequently also smokers, despite the
well-known risks of this association. All physicians should
be aware of this association when they prescribe OC to
adolescents. On a public health level, preventive actions
should target the combined use of OC and cigarettes in
teenagers in order to avoid later consequences on cardio-
vascular disease incidence.
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